Merck to Buy Harpoon Therapeutics for $680 Million

Merck & Co.has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

Merck on Monday said it will pay $23 a share in cash for Harpoon, more than double Friday’s closing price of $10.55 for the South San Francisco, Calif., company.